PAVM Long Call Strategy

PAVM (PAVmed Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

PAVM (PAVmed Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $3.4M, a trailing P/E of 12.17, a beta of 0.64 versus the broader market, a 52-week range of 6-28.44, average daily share volume of 24K, a public-listing history dating back to 2016, approximately 39 full-time employees. These structural characteristics shape how PAVM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.64 indicates PAVM has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a long call on PAVM?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current PAVM snapshot

As of May 15, 2026, spot at $6.57, ATM IV 124.90%, IV rank 21.13%, expected move 35.81%. The long call on PAVM below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on PAVM specifically: PAVM IV at 124.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a PAVM long call, with a market-implied 1-standard-deviation move of approximately 35.81% (roughly $2.35 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated PAVM expiries trade a higher absolute premium for lower per-day decay. Position sizing on PAVM should anchor to the underlying notional of $6.57 per share and to the trader's directional view on PAVM stock.

PAVM long call setup

The PAVM long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With PAVM near $6.57, the first option leg uses a $6.57 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed PAVM chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 PAVM shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$6.57N/A

PAVM long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

PAVM long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on PAVM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on PAVM

Long calls on PAVM express a bullish thesis with defined risk; traders use them ahead of PAVM catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

PAVM thesis for this long call

The market-implied 1-standard-deviation range for PAVM extends from approximately $4.22 on the downside to $8.92 on the upside. A PAVM long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current PAVM IV rank near 21.13% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on PAVM at 124.90%. As a Healthcare name, PAVM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to PAVM-specific events.

PAVM long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. PAVM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move PAVM alongside the broader basket even when PAVM-specific fundamentals are unchanged. Long-premium structures like a long call on PAVM are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current PAVM chain quotes before placing a trade.

Frequently asked questions

What is a long call on PAVM?
A long call on PAVM is the long call strategy applied to PAVM (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With PAVM stock trading near $6.57, the strikes shown on this page are snapped to the nearest listed PAVM chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are PAVM long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the PAVM long call priced from the end-of-day chain at a 30-day expiry (ATM IV 124.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a PAVM long call?
The breakeven for the PAVM long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current PAVM market-implied 1-standard-deviation expected move is approximately 35.81%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on PAVM?
Long calls on PAVM express a bullish thesis with defined risk; traders use them ahead of PAVM catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current PAVM implied volatility affect this long call?
PAVM ATM IV is at 124.90% with IV rank near 21.13%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related PAVM analysis